OncoMatch/Clinical Trials/NCT06405230
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Is NCT06405230 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Pembrolizumab and Dostarlimab for lung cancer, non-small cell.
Treatment: Pembrolizumab · Dostarlimab · Pemetrexed+ (carboplatin or cisplatin) — The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to standard of care treatment in the advanced/metastatic stages.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) identifiable PDL1 status
Identifiable PDL1 status prior to randomisation
Excluded: EGFR sensitizing mutation
NSCLC with known sensitizing EGFR mutations ... from resected tissue at the time of initially surgery and/or tissue biopsy at the time of screening
Excluded: ALK translocation
NSCLC with known ... Anaplastic lymphoma kinase (ALK) translocations ... from resected tissue at the time of initially surgery and/or tissue biopsy at the time of screening
Excluded: ROS1 mutation
NSCLC with known ... c-ros oncogene 1 (ROS1) mutations from resected tissue at the time of initially surgery and/or tissue biopsy at the time of screening
Disease stage
Required: Stage I, II, III
Metastatic disease required
Participants must have biopsy-confirmed recurrence of their initial NSCLC with advanced/metastatic presentation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: surgery — curative resection ± (neo) adjuvant treatment
Participants must have been initially diagnosed with operable Stage 1-3 NSCLC and received curative resection ± (neo) adjuvant treatment
Cannot have received: anti-PD-(L)1 therapy
Exception: allowed if last dose ≥6 months before first 89Zr-durvalumab-PET tracer injection
For participants who received adjuvant therapy that included anti-PD(L)1 Checkpoint inhibitor (CPI) following surgical resection, their last dose of anti-PD(L)1 was <6 months from the date of first 89Zr-durvalumab-PET tracer injection
Cannot have received: any anti-cancer therapy for lung cancer recurrence after initial surgery
Participant has received any form of anti-cancer therapy (e.g., chemotherapy, radiation, immunotherapy) for lung cancer recurrence after initial surgery
Cannot have received: additional anticancer post-surgery±(neo) adjuvant therapy or experimental therapy
Is receiving any additional anticancer post-surgery±(neo) adjuvant therapy or experimental therapy. No other experimental therapies ... are permitted while the participant is receiving study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06405230 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-(L)1 therapy, any anti-cancer therapy for lung cancer recurrence after initial surgery, additional anticancer post-surgery±(neo) adjuvant therapy or experimental therapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 identifiable PDL1 status is a required biomarker for enrollment.
Are patients with EGFR alterations eligible?
No. EGFR sensitizing mutation is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK translocation is an exclusion criterion.
What disease stage is eligible?
Stage I or II or III is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify